Searched for
CRDMO DEVELOPMENT
Cohance Lifesciences to invest USD 18 mn in NJ Bio, Aruka BioCohance Lifesciences announced an eighteen million dollar investment to strengthen its antibody-drug conjugate strategy. This includes thir...- Aragen Life Sciences files draft papers with Sebi to raise funds through IPOAragen Life Sciences has filed its DRHP with Sebi for an IPO comprising a Rs 800 crore fresh issue and an OFS. Proceeds will fund debt repa...
- Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 targetJefferies has initiated coverage on Anthem Biosciences with a Buy rating and Rs 1,050 target, implying around 20% upside. The brokerage is ...
- India's pharma sector must shift from cost competitiveness to innovation, global quality: ExpertsFor the growth of India's pharmaceutical sector, prioritizing innovation and advanced manufacturing is essential. Experts indicate that inc...
- Nomura initiates coverage on this recently-listed CRDMO stock, sees 18% upside despite 22% correctionNomura has initiated coverage on Anthem Biosciences with a Buy rating and a ₹740 target, citing attractive valuations, strong CRDMO positio...
- Cohance Lifesciences and other pharma stocks jump up to 5% after Jefferies initiates Buy recommendationCohance Lifesciences, Divi’s Laboratories, and SAI Life Sciences rallied after Jefferies initiated coverage with ‘Buy’ ratings, citing stro...
- Avendus Fund, SBI Life lead funding in AragenAvendus Future Leaders Fund and SBI Life Insurance have collectively invested ₹300 crore in Aragen Life Sciences, acquiring a 2.5% stake in...
- Anthem Biosciences shares rally 3% after healthy listing. Should you buy now?Anthem Biosciences share price: Anthem’s IPO did not include a fresh issue, with all proceeds going to existing shareholders. Prior to the ...
- Anthem Biosciences' Rs 3,395 crore IPO opens for subscription. Should you bid?Anthem Biosciences launched its IPO on July 14, featuring an offer for sale of Rs 3,395 crore. The Bengaluru-based CRDMO, with a price band...
- Is Anthem Biosciences IPO a risky bet for investors?Anthem Biosciences, a CRDMO, is set to launch an IPO to raise ₹3,395 crore, diluting the promoter group's stake. While revenue and profit h...
- Anthem Biosciences IPO: Rs 3,395 crore IPO to open on July 14Anthem Biosciences' Rs 3,395 crore IPO will open on July 14 as a complete Offer for Sale by promoters and investors. The Bengaluru-based CR...
- India's contract drug makers seek government support in China fightIndia's contract drug makers are seeking government support to remove regulatory hurdles and speed up raw material import clearances. With ...
- India's CRDMO sector can touch USD 25 bn in size by 2035: ReportIndia's CRDMO sector has the potential to reach USD 22-25 billion by 2035, driven by supply chain de-risking, pricing pressures, and demand...
- India becoming an attractive option for global pharmaceutical supply chain: Macquarie ReportIndia's CRDMO industry is projected to grow from USD 7 billion to USD 14 billion by 2028, driven by pharmaceutical outsourcing and regulato...
- Macquarie bullish on Suven Pharma, Divi's Labs, Bluejet and SyngeneMacquarie said that the sector is currently at a turning point, driven by increased pharmaceutical outsourcing due to drug pricing pressure...
- Investing in 2025: ICICIDirect's Pankaj Pandey betting on 4 big themes this yearWe are constructive on markets and believe the recent correction offers a good entry point to start accumulation for long term wealth gener...
- Anthem Biosciences files DRHP for Rs 3,395 crore IPOAnthem Biosciences, a CRDMO, has filed for a Rs 3,395 crore IPO. The offer comprises an OFS by promoters and investors, including True Nort...
- Anthem Biosciences files DRHP for Rs 3,395 crore IPOAnthem Biosciences has filed its DRHP for an IPO. The issue comprises an offer for sale of up to Rs 3,395 crore by promoters and investors....
- Sai Life Science grew fast, but pricing looks expensiveThe issue gives a partial exit to private equity investors TPG Asia and HBM. The promoter share will be diluted from 41.8% to 35.2%. The is...
- Jubilant Pharmova's US arm prepays Rs 626 crore term loanJubilant Pharmova's US subsidiary secured a $75 million term loan, as of March 31, 2024, the company's gross debt stood at Rs. 3,414 crore ...
Load More
